-->

Tag: idecabtagene vicleucel

Home / idecabtagene vicleucel

Categories

CAR T-cell treatment provides significant remission rates in clinical trials

Feb 2023: In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for triple-class exposed multiple myeloma. Abecma (idecabtagene vicleuc...
idecabtagene-vicleucel

The FDA has approved idecabtagene vicleucel for the treatment of multiple myeloma

August 2021: The Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma after four...
idecabtagene-vicleucel

Scan the code